Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This report summarizes the clinical experience of investigators at the istituto Nazionale Tumori in Milan, Italy, with intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) infused over 3 hours plus bolus doxorubicin in women with untreated breast cancer. The overall experience indicates that the combination of paclitaxel/doxorubicin is a very active primary chemotherapy for stage IV breast carcinoma and is associated with manageable toxicity. The results suggest that the incidence of cardiotoxicity and duration of neutropenia can be reduced by limiting the total cumulative dose of doxorubicin to 360 mg/m2 and by adding granulocyte colony-stimulating factor to the primary chemotherapeutic regimen. In addition, the study indicates that continuous treatment of responding patients with single-agent paclitaxel after this combination increases the patients' chances of complete response. These favorable results indicate that this regimen could be a very effective treatment option as adjuvant or neoadjuvant chemotherapy in women with early stage operable breast cancer as well as those with advanced breast cancer.

Original languageEnglish
JournalSeminars in Oncology
Volume24
Issue number1 Suppl 3
Publication statusPublished - Feb 1997

Fingerprint

Paclitaxel
Doxorubicin
Breast Neoplasms
Drug Therapy
Granulocyte Colony-Stimulating Factor
Neutropenia
Italy
Research Personnel
Incidence
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

@article{7eeffb67028c4bf889eb062867e37814,
title = "Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.",
abstract = "This report summarizes the clinical experience of investigators at the istituto Nazionale Tumori in Milan, Italy, with intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) infused over 3 hours plus bolus doxorubicin in women with untreated breast cancer. The overall experience indicates that the combination of paclitaxel/doxorubicin is a very active primary chemotherapy for stage IV breast carcinoma and is associated with manageable toxicity. The results suggest that the incidence of cardiotoxicity and duration of neutropenia can be reduced by limiting the total cumulative dose of doxorubicin to 360 mg/m2 and by adding granulocyte colony-stimulating factor to the primary chemotherapeutic regimen. In addition, the study indicates that continuous treatment of responding patients with single-agent paclitaxel after this combination increases the patients' chances of complete response. These favorable results indicate that this regimen could be a very effective treatment option as adjuvant or neoadjuvant chemotherapy in women with early stage operable breast cancer as well as those with advanced breast cancer.",
author = "L. Gianni and G. Capri",
year = "1997",
month = "2",
language = "English",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 Suppl 3",

}

TY - JOUR

T1 - Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.

AU - Gianni, L.

AU - Capri, G.

PY - 1997/2

Y1 - 1997/2

N2 - This report summarizes the clinical experience of investigators at the istituto Nazionale Tumori in Milan, Italy, with intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) infused over 3 hours plus bolus doxorubicin in women with untreated breast cancer. The overall experience indicates that the combination of paclitaxel/doxorubicin is a very active primary chemotherapy for stage IV breast carcinoma and is associated with manageable toxicity. The results suggest that the incidence of cardiotoxicity and duration of neutropenia can be reduced by limiting the total cumulative dose of doxorubicin to 360 mg/m2 and by adding granulocyte colony-stimulating factor to the primary chemotherapeutic regimen. In addition, the study indicates that continuous treatment of responding patients with single-agent paclitaxel after this combination increases the patients' chances of complete response. These favorable results indicate that this regimen could be a very effective treatment option as adjuvant or neoadjuvant chemotherapy in women with early stage operable breast cancer as well as those with advanced breast cancer.

AB - This report summarizes the clinical experience of investigators at the istituto Nazionale Tumori in Milan, Italy, with intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) infused over 3 hours plus bolus doxorubicin in women with untreated breast cancer. The overall experience indicates that the combination of paclitaxel/doxorubicin is a very active primary chemotherapy for stage IV breast carcinoma and is associated with manageable toxicity. The results suggest that the incidence of cardiotoxicity and duration of neutropenia can be reduced by limiting the total cumulative dose of doxorubicin to 360 mg/m2 and by adding granulocyte colony-stimulating factor to the primary chemotherapeutic regimen. In addition, the study indicates that continuous treatment of responding patients with single-agent paclitaxel after this combination increases the patients' chances of complete response. These favorable results indicate that this regimen could be a very effective treatment option as adjuvant or neoadjuvant chemotherapy in women with early stage operable breast cancer as well as those with advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031068876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031068876&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 Suppl 3

ER -